Cullinan Oncology

Cullinan Oncology, Inc. is a biopharmaceutical company engaged in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cullinan Therapeutics, Inc. is a biopharmaceutical company engaged in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference, being held in New York on November 18 and 19, 2024.

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced the upcoming presentation of preclinical data for CLN-978, a novel CD19xCD3 bispecific T cell engager, at American College of Rheumatology (ACR) Convergence 2024, taking place in Washington, D.C. from November 14-19, 2024.

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

CLN-978 is the first development stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases CAMBRIDGE, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company's Investigational New Drug (IND) Application for CLN-978 and its global Phase 1 clinical trial may proceed in the U.S. to assess CLN-978 in patients with moderate to severe systemic lupus erythematosus (SLE).

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

Phase 1 clinical trial is designed to assess the safety, pharmacokinetics and initial clinical activity of CLN-978 for patients with systemic lupus erythematosus

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Updated data show consistent objective response rate of 40% and manageable safety profile in patients with non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations treated with zipalertinib who progressed on or after prior amivantamab treatment

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its participation in the following upcoming investor conferences:

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had progressed after prior amivantamab treatment Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had progressed after prior amivantamab treatment

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer and Jeffrey Jones, MD, MBA, Chief Medical Officer, will participate in a fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA, being held virtually on May 28 and 29, 2024.

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung cancer (NSCLC) with oncogenic mutations

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at ASCO 2024 Annual Meeting

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment of Mary Kay Fenton as Chief Financial Officer, beginning April 29.

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid tumors will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31-June 4, 2024. The data will include first results from the dose escalation cohort of CLN-619 in combination with checkpoint inhibitor pembrolizumab and updated results from the monotherapy dose escalation cohort in patients with advanced solid tumors.

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

Financing includes new and existing leading life sciences institutional investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 Cullinan to host a virtual investor event on April 16 at 8:00 am ET CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (formerly Cullinan Oncology, Inc.) (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that it has entered into a stock purchase agreement with certain institutional and accredited investors for a private placement of approximately $274.0 million of shares of its common stock at a price of $19.00 per share and, in lieu of common stock to certain investors, $6.0 million of pre-funded warrants to purchase shares of its common stock at a price of $18.999 per pre-funded warrant.

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

Cullinan remains on track to report additional solid tumor dose escalation data for CLN-619 in the second quarter of 2024 and recently received FDA clearance for an IND to evaluate CLN-619 in relapsed/refractory multiple myeloma

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Company will initiate Phase 1 study of CLN-619 for relapsed or refractory multiple myeloma, first MICA/B antibody clinical study in hematologic malignancies

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced its participation in the following upcoming investor conferences:

Cullinan Oncology to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) --  Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that Chief Executive Officer, Nadim Ahmed, will present at the 42nd Annual J.P. Morgan Healthcare Conference, being held January 8-11, 2024 in San Francisco, CA. Mr. Ahmed's presentation is scheduled for Thursday, January 11, at 10:30 am PST (1:30 pm EST).

Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic, targeted oncology therapies, today announced that the first patient has been dosed with CLN-617 in a Phase 1 clinical trial. This is a first-in-human, multi-center, open label study designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of CLN-617 alone and in combination with pembrolizumab, a programmed death receptor-1 (PD-1) targeted checkpoint inhibitor, in patients with advanced solid tumors.

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

Cullinan to provide clinical data updates on three novel targeted oncology programs and complete enrollment in the pivotal Phase 2b portion of the zipalertinib REZILIENT1 study in 2024

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Five abstracts accepted for poster presentation at the Society for Immunotherapy of Cancer 2023 Annual Meeting Preliminary clinical biomarker data for anti-MICA/B antibody, CLN-619, supports proposed mechanism of action and demonstrates that the observed monotherapy clinical activity was seen in patients with tumors not typically responsive to checkpoint inhibitor therapy   Data highlight progress of Cullinan's diverse pipeline including CLN-619, an anti-MICA/B antibody; CLN-418, a B7H4X4-1BB-bispecific immune activator; CLN-978, a CD19XCD3 bispecific T cell engager; and CLN-617, a fusion protein harnessing IL-2 and IL-12 cytokines CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan”), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that it will present data across four distinct immuno-oncology programs in five poster presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting taking place November 1-5 in San Diego.

Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

Cullinan Oncology's stock remains below cash value despite positive phase 1 trial data for its second asset, CLN-619. The company's lead asset, Zipalertinib, has shown promising results in treating EGFRex20ins NSCLC, positioning it as a potential treatment of choice in this patient population. Cullinan Oncology has initiated a phase 3 study for Zipalertinib and has released encouraging data for its second candidate, CLN-619, in heavily pretreated patients.

Cullinan Oncology: Inexplicably Trading Below Cash Despite Robust Data

Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer (NSCLC) patients (REZILIENT-3) open to enrollment

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

CAMBRIDGE, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating CLN-978 for the treatment of relapsed/refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL).

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Phase 3 trial will assess progression-free survival of zipalertinib plus chemotherapy versus chemotherapy in adult patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR exon 20 insertion mutations PRINCETON, N.J. and CAMBRIDGE, Mass.

News for Cullinan Oncology Stock (CGEM)